Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Ascendis Pharma A (ASND) Enterprise Value (2016 - 2025)

Ascendis Pharma A's Enterprise Value history spans 8 years, with the latest figure at -$429.8 million for Q4 2023.

  • For Q4 2023, Enterprise Value rose 42.72% year-over-year to -$429.8 million; the TTM value through Dec 2023 reached -$429.8 million, up 42.72%, while the annual FY2023 figure was -$432.1 million, 44.26% up from the prior year.
  • Enterprise Value for Q4 2023 was -$429.8 million at Ascendis Pharma A, up from -$750.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$429.8 million in Q4 2023 and bottomed at -$857.0 million in Q4 2020.
  • The 5-year median for Enterprise Value is -$750.3 million (2022), against an average of -$695.9 million.
  • The largest annual shift saw Enterprise Value crashed 108.74% in 2019 before it surged 42.72% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$662.0 million in 2019, then dropped by 29.45% to -$857.0 million in 2020, then rose by 8.96% to -$780.3 million in 2021, then increased by 3.83% to -$750.3 million in 2022, then soared by 42.72% to -$429.8 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Enterprise Value are -$429.8 million (Q4 2023), -$750.3 million (Q4 2022), and -$780.3 million (Q4 2021).